Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Schlieren, Switzerland, Oct. 26, 2017 -- InSphero AG and Charles River Laboratories International, Inc. today announced a partnership through which Charles River will license its collection of patient-derived xenograft (PDX) tumors to InSphero. Additionally, Charles River will leverage InSphero’s proprietary 3D cell culture technology to further extend and complement its pre-clinical services, using in vitro 3D InSight™ Tumor Microtissues derived from its existing PDX collection.
|
|||||||||||
“Over the past year, we have seen an increased demand from our oncology clients for enhanced speed and efficiency in early drug discovery,” said Birgit Girshick, Corporate Senior Vice President, Global Discovery Services at Charles River. “In vitro discovery platforms offer a strong solution, and our partnership with InSphero significantly bolsters our capabilities in this field.”
In vitro 3D solutions enable the evaluation of a compound’s potency compared to standard-of-care drugs. This in vitro testing provides for identification of the most promising drug candidates, tumor histotypes and molecular subtypes. Data collected in these tests can then be used to select PDX models for subsequent in vivo efficacy tests. The data can also be used to run systematic combination therapy studies over a range of concentrations and to correlate the tumor response with molecular data.
“Licensing Charles River’s robust library of PDX tumor models significantly expands our current disease model portfolio in diabetes and liver fibrosis” said Jan Lichtenberg, Ph.D., Chief Executive Officer and Co-Founder at InSphero. “The combination of their extensive background in PDX tumors, combined with our proprietary and industry-validated 3D cell culture technology, will help pave the way for future breakthroughs. Expanding our 3D InSight™ Discovery Platform to Charles River’s PDX models will offer scalability, speed and unmet biological relevance in vitro.”
To learn more about InSphero 3D InSight™ Tumor Microtissues and Oncology Drug Discovery Services, visit www.insphero.com.
To learn more about Charles River’s oncology research capabilities, visit www.criver.com.
###
InSphero contacts
Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
[email protected]
Dr. Jan Lichtenberg
Chief Executive Officer and Co-founder
Phone +41 44 5150490
[email protected]
About InSphero
InSphero is the partner of choice for leading pharmaceutical and biotechnology companies to bring safer, more effective drugs to market faster through its robust and highly physiologically relevant suite of 3D InSight™ Microtissues and Services. InSphero patent-pending technologies and methods enable large-scale, reproducible production of scaffold-free 3D microtissues driven solely by cellular self-assembly. InSphero 3D InSight™ Discovery Platforms include assay-ready and custom 3D disease models derived from primary human liver, pancreas, and tumor tissues that provide unrivalled biological insight into liver fibrosis, diabetes, and cancer. InSphero microtissues are thoroughly validated to ensure the highest quality, certified for use in a variety of assays, and shipped globally to customers in a patented, easy-to-use spheroid-optimized format, or accessible through contract research services. For more information, visit www.insphero.com.
Follow us on Twitter and LinkedIn.
Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/ee4287e7-0078-4057-87fb-e9357ccee417
Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/74841018-b4e8-4e66-b40d-dbfac8c3167f
Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/ac996a27-db1e-4958-9604-d8c3c5c8c27f
Randy Strube InSphero AG 800-619-6800 [email protected]
